Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Clinical trial NCT04340596 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04340596
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-21
- Primary completion
- 2026-05-07
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.